Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Neurologists who Treat Epilepsy (US)

Articles with lock require a subscription to GLG News | Request a free trial
December 1, 2008
Miami Site May Succeed in Quick Recruitment of a Study Population
Analysis of: Miami Jewish Home and Hospital, Berma Research Group and Segal Institute for Clinical Research Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimer's Disease | pharmalive.com
Author: GLG Expert Contributor
The CONNECTION study is important in that Dimebon has a mode of action different from all other current treatments. If the results of the phase II study are corroborated, Dimebon may be an important, additional treatment modality.
December 1, 2008
Sales of Infuse product will likely decline with closer scrutiny of off-label use
Analysis of: Medtronic Says Device for Spine Faces Probe | online.wsj.com
Author: Wayel Kaakaji, Chief Executive Officer and Medical Director, Spinal and Neurosurgical Institute
Medtronic might see a significant drop in its sales as a result of closer scrutiny of off-label use of its products.  Infuse has been a cash cow for Medtronic, and if sales drop, it will reflect deeply in the sales numbers.
December 1, 2008
Accuray Cyberknife Sales About to Go Through The Roof
Analysis of: Experts Debate CyberKnife for Prostate Cancer | www.washingtonpost.com
Author: Wayel Kaakaji, Chief Executive Officer and Medical Director, Spinal and Neurosurgical Institute
Prostate cancer can be treated by Cyberknife, and the numbers of patients treated and the number of units sold by Accuray (ARAY:NASDAQ) will very likely increase dramatically over the next 5-10 years. 
Daniel WynnNovember 17, 2008
"Tamper-Proof" -- A Significant Gain to Whom??
Analysis of: FDA Asks if Pain Pill Is Tamper-Proof | online.wsj.com
Author: Daniel Wynn, Director, Clinical Research, Consultants In Neurology Ltd.
Abuse resistant long acting narcotics offer benefit as they are less desirable to those who might wish a quick high via snorting, injecting crushed time-release narcotic. Unfortunately, given the higher cost than long acting generics and increased pressure on physicians to prescribe generics, expect...
November 10, 2008
Wild speculation
Analysis of: Autism linked with rainfall in study | www.boston.com
Author: GLG Expert Contributor
I do not believe that any conclusions can be drawn from these data unless they can be confirmed by a larger, more wide ranging population sampling.
November 4, 2008
Vimpat approved ONLY for adjunctive therapy of epilepsy
Analysis of: UCB's Vimpat(R) approved by U.S. FDA as adjunctive therapy for partial onset seizures in adults | www.pipelinereview.com
Author: GLG Expert Contributor
Vimpat was developed to have applicability to other disease processes including neuropathic pain. The limited indication approved for Vimpat suggests the data for other potential uses was not very robust (that had been my observation based on the neuropathic pain studies). Although UCB may be developing...
November 3, 2008
UCB's Vimpat (lacosamide) receives FDA approval
Analysis of: UCB's Vimpat(R) approved by U.S. FDA as adjunctive therapy for partial onset seizures in adults | www.pipelinereview.com
Author: GLG Expert Contributor
FDA has approved lacosamide for add-on therapy of partial onset seizures.  It will be marketed by UCB under the brand name Vimpat.
October 10, 2008
Mixed Blessings for Medtronic in Professional Spinal Surgery Organizations
Analysis of: Letter to CMS from a Coalition of Spine Care Professional Societies | www.spine.org
Author: Wayel Kaakaji, Chief Executive Officer and Medical Director, Spinal and Neurosurgical Institute
The data presented by multiple professional societies does not lend clinical support of many Medtronic products in the Medicare population.  The data does not support the use of disc arthroplasty in the Medicare population, and does not find any clinical advantage of kyphoplasty over vertebroplasty. ...
October 9, 2008
New electrode may expand the capabilities of the Advance System from Neurometrix
Analysis of: NeuroMetrix Receives FDA 510(k) Clearance For UNIVERSAL(TM) Electrodes Used In The Performance Of Nerve Conduction Studies | www.medicalnewstoday.com
Author: Wayel Kaakaji, Chief Executive Officer and Medical Director, Spinal and Neurosurgical Institute
New electrode will increase the capabilities of the Advance device from Neurometrix, potentially leading to more sales of the disposable electrodes The increased capabilities may also increase the number of practicioners interested in the Advance system, generating more sales for the company
September 25, 2008
Proton beam therapy has no proven advantage
Analysis of: Proton Radiotherapy: A Review | www.nytimes.com
Author: Wayel Kaakaji, Chief Executive Officer and Medical Director, Spinal and Neurosurgical Institute
The cost of proton beam installations is massive, and is not justified in light of available litterature regarding the superiority of this therapy. There are only a handful of tumors, such as chordoma, where the proton beam therapy is recommended over other types of radiation.  The higher compensation...

Page : 1 2 3 4 5 6 7 8 9 10 Next1 to 10 of 150

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-05T01:45:24.617